Abstract:Background Chronic hepatitis B is a primary cause of liver-related death. Interferon alpha (IFN-α) is able to inhibit the replication of hepadnavirus, and the sustained and stable expression of IFN-α at appropriate level may be beneficial to HBV clearance. With the development of molecular cloning technology, gene therapy plays a more and more important role in clinical practice. In light of the findings, an attempt to investigate the anti-HBV effects mediated by a eukaryotic expression plasmid (pSecTagB-IFN-α) in vitro was carried out. Methods HBV positive cell line HepG2.2.15 and its parental cell HepG2 were transfected with pSecTagB-IFN-α or empty plasmid by using Lipofectamine™ 2000 reagent. The expression levels of IFN-α were determined by reverse transcriptase polymerase chain reaction (RT-PCR) and ELISA methods. The effects of pSecTagB-IFN-α on HBV mRNA, DNA and antigens were analyzed by real-time fluorescence quantitative PCR (qRT-PCR) and ELISA assays. RT-PCR, qRT-PCR and western blot were employed to investigate the influence of pSecTagB-IFN-α on IFN-α-induced signal pathway. Furthermore, through qRT-PCR and ELISA assays, the suppressive effects of endogenously expressed IFN-α and the combination with lamivudine on HBV were also examined. Results pSecTagB-IFN-α could express efficiently in hepatoma cells, and then inhibited HBV replication, characterized by the decrease of HBV S gene (HBs) and HBV C gene (HBc) mRNA, the reduction of HBV DNA load, and the low contents of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg). Mechanism research showed that the activation of Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signal pathway, the up-regulation of IFN-α-induced antiviral effectors and double-stranded (ds) RNA sensing receptors by delivering pSecTagB-IFN-α, could be responsible for these phenomena. Furthermore, pSecTagB-IFN-α vector revealed effectively anti-HBV effect than exogenously added IFN-α. Moreover, lamivudine combined with endogenously expressed IFN-α exhibited stronger anti-HBV effect than with exogenous IFN-α. Conclusion Our results showed that endogenously expressed IFN-α can effectively and persistently inhibit HBV replication in HBV infected cells. These observations opened a promising way to design new antiviral genetic engineering drugs based on IFN-α.

Study on the Inhibition of Hepatitis B Virus by Single-chain Fv Fragment

Intracellular-Delivery Of A Single-Chain Antibody Against Hepatitis B Core Protein Via Cell-Penetrating Peptide Inhibits Hepatitis B Virus Replication In Vitro

An E. Coli-Produced Single-Chain Variable Fragment (scfv) Targeting Hepatitis B Virus Surface Protein Potently Inhibited Virion Secretion.

Interaction of S17 Antibody with the Functional Binding Region of the Hepatitis B Virus Pre-S2 Epitope

Isolation of the neutralization ScFvs Against HBV infection from the Immunized Population.

Selection of affinity-improved neutralizing human scFv against HBV PreS1 from CDR3 VH/VL mutant library

Humanization of Therapeutic Antibody of One Hepatitis B Virus and Identification of Its Biological Activity

An Hepatitis B Virus Surface Antigen Specific Single Chain of Variable Fragment Derived from A Natural Immune Antigen Binding Fragment Phage Display Library is Specifically Internalized by Hepg2.2.15 Cells

An Aptamer Targets Hbv Core Protein And Suppresses Hbv Replication In Hepg2.2.15 Cells

Variable Fragment of Heavy Chain Antibody Against TP Region of Hepatitis B Virus Polymerase Inhibits Replication of Hepatitis B Virus in Vitro

In Vivo Binding Activity of Recombinant ScFv Against HBsAg in HBV Transgenic Mice

[Expression of Anti-Hbc Single-Chain Variable Fragment Mediated by Recombinant Replication Defective Adenovirus in Vitro].

The characterization and structural basis of a human broadly binding antibody to HBV core protein

Targeted Inhibition of Hbv Gene Expression by Single-Chain Antibody Mediated Small Interfering Rna Delivery

Expression and Immunoactivity of Chimeric Particulate Antigens of Receptor Binding Site-Core Antigen of Hepatitis B Virus

Neutralization Effects of Antibody Elicited by Chimeric HBV S Antigen Viral-Like Particles Presenting HCV Neutralization Epitopes.

Vaccination with A Fusion Dna Vaccine Encoding Hepatitis B Surface Antigen Fused to the Extracellular Domain of Ctla4 Enhances Hbv-Specific Immune Responses in Mice: Implication of Its Potential Use As A Therapeutic Vaccine

The Recombinant Antibody HBsAg-Fab of Hepatitis B Virus to Block Hepatitis B Reinfection after Liver Transplantation: a Research in Vitro

The Anti-Hbv Effect Mediated by a Novel Recombinant Eukaryotic Expression Vector for IFN-α

Efficient Inhibition of Hepatitis B Virus Infection by a Pres1-Binding Peptide

Locked Nucleic Acid Couples with Fok I Nucleases to Target and Cleave Hepatitis B Virus's Gene in Vitro.